| P50 | author | Meritxell Huch | Q42800662 |
| | Joris A Veltman | Q57687954 |
| | Alexander Hoischen | Q75069951 |
| | Jayne Y Hehir-Kwa | Q90648515 |
| P2093 | author name string | Ronald Roepman | |
| | Joost P H Drenth | |
| | Wybrich R Cnossen | |
| | Rolph Pfundt | |
| | Jody Salomon | |
| | René H M Te Morsche | |
| | Marloes Steehouwer | |
| | Rob Woestenenk | |
| | Edgar S Wills | |
| | Martijn J Banning | |
| P2860 | cites work | A review of trisomy X (47,XXX) | Q21093168 |
| | Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1 | Q24538950 |
| | A mosaic activating mutation in AKT1 associated with the Proteus syndrome | Q24598593 |
| | Polycystin-1: a master regulator of intersecting cystic pathways | Q26826955 |
| | Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis | Q28237611 |
| | Long-term culture of genome-stable bipotent stem cells from adult human liver | Q28254408 |
| | A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation | Q28590393 |
| | Polycystic kidney disease | Q33709685 |
| | Whole chromosome instability caused by Bub1 insufficiency drives tumorigenesis through tumor suppressor gene loss of heterozygosity | Q33743993 |
| | Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide | Q33827422 |
| | Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease | Q33979298 |
| | Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. | Q33998303 |
| | Hepatoblastoma and APC gene mutation in familial adenomatous polyposis. | Q34410700 |
| | Loss of heterozygosity is present in SEC63 germline carriers with polycystic liver disease | Q34500168 |
| | Cystic disease in women: clinical characteristics and medical management | Q35077660 |
| | Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis | Q35872096 |
| | A novel long-range PCR sequencing method for genetic analysis of the entire PKD1 gene | Q36081160 |
| | Evaluation of the 3p21.3 tumour-suppressor gene cluster | Q36833529 |
| | Somatostatin analogues for treatment of polycystic liver disease | Q37824573 |
| | A recurrent 1.71 Mb genomic imbalance at 2q13 increases the risk of developmental delay and dysmorphism | Q37831384 |
| | Diagnosis and management of polycystic liver disease | Q38072284 |
| | Polycystic liver disease: ductal plate malformation and the primary cilium | Q38186149 |
| | Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling | Q38289224 |
| | Overexpression of PKD1 causes polycystic kidney disease | Q41780316 |
| | Unified criteria for ultrasonographic diagnosis of ADPKD. | Q41829694 |
| | Identification of germline and somatic mutations affecting the retinoblastoma gene | Q41830287 |
| | Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease | Q41891142 |
| | Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease | Q42546669 |
| | Tumor susceptibility of Rassf1a knockout mice | Q45234570 |
| | Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. | Q46269311 |
| | Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial | Q47715661 |
| | Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. | Q53326694 |
| | Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. | Q53667326 |
| | Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. | Q53879309 |
| | A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? | Q73711189 |
| | Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene | Q74604719 |
| | Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma | Q77977516 |
| | Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease | Q77998428 |
| | Molecular cytogenetic aberrations in autosomal dominant polycystic kidney disease tissue | Q78826978 |
| | Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease | Q79887081 |
| | Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort | Q80796878 |
| | Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors | Q81387451 |
| | Extrarenal manifestations of autosomal dominant polycystic kidney disease | Q83169966 |
| | Somatic loss of polycystic disease genes contributes to the formation of isolated and polycystic liver cysts | Q85642900 |
| | Genomic instability in patients with autosomal-dominant polycystic kidney disease | Q86562749 |
| P433 | issue | 12 | |
| P921 | main subject | polycystic liver disease | Q246002 |
| P304 | page(s) | 1707-1714 | |
| P577 | publication date | 2016-08-24 | |
| P1433 | published in | European Journal of Human Genetics | Q2155433 |
| P1476 | title | Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes | |
| P478 | volume | 24 | |